Receive news by e-mail

#
 

Enter your e-mail in the field below to receive directly the news that appears on this page.

 

topics : related - all Explore

Shopping

Top Product

Reproduction And Responsibility: The Regulation Of New Biotechnologies: A Report Of The President's Council On Biotechnologies: Pre-publication Version

Compare prices

  1. 2. Nature's Operating Instructions: The True Biotechnologies (The Bioneers Series)
  2. 3. Novel Biotechnologies for Biocontrol Agent Enhancement and Management (NATO Science for Peace and Security Series A: Chemistry and Biology)
  3. 4. Bodies, Commodities, and Biotechnologies: Death, Mourning, and Scientific Desire in the Realm of Human Organ Transfer (Leonard Hastings Schoff Lectures)
  4. 5. Bodies, Commodities, and Biotechnologies: Death, Mourning, and Scientific Desire in the Realm of Human Organ Transfer (Leonard Hastings Schoff Lectures)

Shopping Categories

  1. 1. Cell Phones
  2. 2. Smartphones
  3. 3. Digital Cameras
  4. 4. Laptop Computers
  5. 5. Processors
  6. 6. Motherboards
  7. 7. LCD Monitors
  8. 8. Graphics Cards
  9. 9. GPS
  10. 10. Digital Camcorders
  11. 11. Printers
  12. 12. Desktop Computers
  13. 13. Sedans
  14. 14. Coupes & Convertibles
  15. 15. 4x4

Wikio Shopping

  1. 1. Automotive
  2. 2. Beauty & Fragrances
  3. 3. Books
  4. 4. Car/Motorbike
  5. 5. CD
  6. 6. Clothing, Accessories & Shoes
  7. 7. Communication
  8. 8. Computers
  9. 9. DVD
  10. 10. Electronics
  11. 11. Flowers & Gifts
  12. 12. Gourmet & Foods
  13. 13. Health & Personal Care
  14. 14. Home & Garden
  15. 15. Hotels
  16. 16. Household Appliances
  17. 17. Jewelry & Watches
  18. 18. Musical Instruments
  19. 19. Sports & Outdoors
  20. 20. Toys & Baby
  21. 21. Video Games

Participate



Biotechnologies



Sort by : relevance - date - popularity
4Vote!

Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition

CAMBRIDGE, Mass., Nov. 7, /PRNewswire/ -- Research projects in the areas of mathematics and biochemistry scored top marks this evening, as Tim Kunisky of Livingston, NJ and the team of Benjamin Song and Quan (Jack) Chen of Audubon, PA received the highest honors at the Region Five Finals of the 2009 Siemens Competition in Math, Science & Technology, the nation's premier high school science competition....

4Vote!

Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity

MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Most patients with hereditary angioedema (HAE) have prodromal symptoms that signal an oncoming HAE attack giving the patients sufficient time to initiate treatment and decrease the morbidity associated with that attack, according to survey findings presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Early...

4Vote!

Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care

MIAMI BEACH, Fla., Nov. 7 /PRNewswire/ -- Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious genetic disorder, according to data presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. The results come from a self-reported survey of patients...

5Vote!

Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering

SAN DIEGO, Nov. 6 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

5Vote!

Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th

AURORA, Ontario, Nov. 6 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading product...

4Vote!

Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results

[NEWS] LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ — BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009. “We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously reco…...

5Vote!

GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update

[NEWS] ATLANTA, Nov. 6 /PRNewswire-FirstCall/ — GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (“GeoVax” or “the Company”), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced its third quarter 2009 financial results and provided an operational update....

5Vote!

Novavax Reports Third Quarter 2009 Financial Results

[NEWS] ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ — Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the third quarter ended September 30, 2009 and reviewed its recent accomplishments and upcoming milestones. Novavax's net loss for the third quarter of 2009 was $7.5 million, or $0.08 per share, compared to a net loss of $7.8 million, or $0.12 per share, for the same period...

5Vote!

Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results

LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.

5Vote!

Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009

[NEWS] Achieves Record Quarterly Gross Margin of $92 Million WOODCLIFF LAKE, N.J., Nov. 6 /PRNewswire-FirstCall/ — Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported results for the third quarter ended October 3, 2009. For the third quarter ended October 3, 2009, Par reported total revenues of $294.8 million an…

5Vote!

Bioniche Reports Fiscal 2010 First Quarter Results And Achievement of First Milestone Under ...

[NEWS] - quarter-end cash of $13.4 million before milestone -<br /><br /> (all figures are in Canadian dollars unless otherwise noted)<br /> BELLEVILLE, ON, Nov. 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September...

5Vote!

Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November...

5Vote!

DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results

[NEWS] Q3 Domestic PDT revenues up 32% year over year; Q3 Non-GAAP loss improves 86% year over year to ($0.2) million WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ — DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today...

5Vote!

EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus

VIENNA, Austria, November 6 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America.

5Vote!

Magnetic nanoparticles to simultaneously diagnose, monitor and treat

[NEWS] Contact: Joe Winters joseph.winters@iop.org 44-020-747-04815 Institute of Physics Whether it's magnetic nanoparticles (mNPs) giving an army of 'therapeutically armed' white blood cells direction to invade a deadly tumour's territory, or the use of mNPs to target specific nerve channels and induce nerve-led behaviour (such as th…

The 2 latest articles published by users on Biotechnologies :

5Vote!

Genentech, Inc. - Financial and Strategic Analysis Review

Genentech, Inc. - Financial and Strategic Analysis Review        - aarkstore

Genentech, Inc. - Financial and Strategic Analysis Review Summary : Genentech, Inc. (Genentech) is a biotechnology company focused on research and development, manufacturing, and marketing of biotherapeutics. Genentech is developing the drugs across the unmet medical needs in cancer, asthma and angiogenic disorders. Major focus of Genentech is on three areas namely; oncology, immunology, and tissue...

4Vote!

MedImmune, Inc. - Strategic Analysis Review

MedImmune, Inc. - Strategic Analysis Review        - aarkstore

MedImmune, Inc. - Strategic Analysis Review Summary MedImmune, LLC.( MedImmune), a biotechnology company focused on the development, manufacture and commercialization of medicines for the indications in Infectious Diseases, Oncology, Inflammatory Disease, cardiovascular, gastrointestinal disease and neuroscience. Its marketed products include Synagis, Ethyol, FluMist and other products. It is headquartered...